E-mail: andrea.biondi@unimib.it
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Collaboration between Activating Mutations in JAK2 and Trisomy 21 in the Acute Lymphoblastic Leukemias of Down Syndrome (DS).
- Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study
- Efficacy and Safety of Imatinib on Top of BFM-Like Chemotherapy in Pediatric Patients with Ph+/BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL). the EsPhALL Study
- IKZF1 DELETION STATUS DISCRIMINATES FOR OUTCOME IN IMATINIB-TREATED BCR-ABL1-POSITIVE CHILDHOOD ALL
- Impact of Additional Cytogenetic Abnormalities and Variant t(9;22) at Diagnosis on Prognosis of Childhood Chronic Myelogenous Leukemia : The Experience of the International Registry for CML in Children and Adolescents (I-CML-Ped Study)
- Prognostic Value of Immunophenotype In Infant ALL – Results of the INTERFANT99 Study
- RAG-Mediated Recombination Is The Predominant Driver Of Oncogenic Rearrangement In ETV6-RUNX1 Acute Lymphoblastic Leukemia
- Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
- Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study
- Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)
- The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration
- The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results
- The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment
